1. Home
  2. GLP vs SNDX Comparison

GLP vs SNDX Comparison

Compare GLP & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Partners LP

GLP

Global Partners LP

HOLD

Current Price

$49.26

Market Cap

1.6B

Sector

Energy

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$17.41

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLP
SNDX
Founded
2005
2005
Country
United States
United States
Employees
4700
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
GLP
SNDX
Price
$49.26
$17.41
Analyst Decision
Hold
Strong Buy
Analyst Count
1
13
Target Price
$46.00
$38.69
AVG Volume (30 Days)
79.2K
1.5M
Earning Date
05-08-2026
04-30-2026
Dividend Yield
6.40%
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
$64.13
$107.19
Revenue Next Year
$11.74
$41.88
P/E Ratio
$23.28
N/A
Revenue Growth
N/A
627.84
52 Week Low
$39.58
$8.59
52 Week High
$56.51
$25.59

Technical Indicators

Market Signals
Indicator
GLP
SNDX
Relative Strength Index (RSI) 53.87 26.91
Support Level $45.18 $14.53
Resistance Level N/A $22.40
Average True Range (ATR) 1.67 0.82
MACD -0.08 -0.15
Stochastic Oscillator 50.27 9.08

Price Performance

Historical Comparison
GLP
SNDX

About GLP Global Partners LP

Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the GDSO segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: